Recently, autologous cell therapy using tumor-infiltrating lymphocytes (TILs) has been approved by the United States (US) Food and Drug Administration (FDA) to treat patients with unresectable or metastatic melanoma, further bolstering the already rapid development of novel CD8+ T cell-involved therapy [3]. The gene discussed is CD8A; the disease is neoplasm.